Single Use Bioreactor Market worth $470.9 Million by 2019, According to a New Study on ASDReports

Friday 14 November 2014, Amsterdam

The new report now on ASDReports, provides a detailed overview of major drivers, restraints, challenges, opportunities, current market trends and strategies impacting the global market along with estimates and forecast of revenue.

The global single use bioreactor (SUBs) market is poised to reach $470.9 million by 2019 from $202.5 million in 2014, at a CAGR of 18.4% from 2014 to 2019.

Factors such as low operational costs, lesser requirement of monitoring and maintenance than traditional bioreactors, ease in culturing of marine microorganism such as algae, and low energy consumption are the factors driving the growth of the SUB market. In addition, the tremendous growth potential of the biologics market is offering robust growth opportunities to market players. However, low volume capacity and lack of availability of sterilized sensors are hindering the growth of this market.

The market is segmented on the basis of molecule type, type of cell, technology, end user, and region. Based on molecule type, the market is segmented into monoclonal antibodies (MAbs), vaccines, gene therapy, recombinant proteins, stem cells, and others (growth factors, interferons, antisense, RNA interference). MAbs accounted for the majority of the global market in 2014.

On the basis of type of cell, the market is broadly classified into mammalian cells, bacterial cells, yeast cells and others (insect cells and plant cells). Mammalian cells are the largest and fastest-growing segment of the market. The large share of this market can be attributed to the higher efficacy of biomolecules expressed by mammalian cells.

The technology segment is categorized into the wave-induced motion SUBs, stirred SUBs, single-use bubble column bioreactors, and others (single-use reactors with vertically perforated discs and single-use hybrid reactors). The wave-induced motion SUB segment accounted for the largest share and is estimated to grow at the fastest rate in the forecast period.

Based on end users, the market is segmented into R&D department (CROs, biopharmaceutical manufacturers, and research institutes) and biopharmaceutical manufacturers. The R&D end-user segment accounted for the major market share in 2014. The biopharmaceutical manufacturers segment, on the other hand will witness the highest growth rate.

On the basis of region, the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW). In 2014, Europe is expected to account for the largest share of the market, followed by North America. Both markets are estimated to register double-digit growth rates over the next five years. However, Asia-Pacific is expected to register a higher growth rate during the forecast period, owing to huge investment opportunities available to biologics manufacturers in this region. Growth of the SUB market in the Asia-Pacific region will revolve around China, India, Australia, South Korea, Taiwan and countries in the Middle East.

Major players operating in the SUB market are Thermo Fischer Scientific, Inc. (U.S.), Sartorius AG (Germany), Merck KGaA (Germany), GE Healthcare (U.S.), and Pall Corporation (U.S.).